Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
Open accessThe DOI matches its Crossref record; 67 of the 69 references it cites were found in a registry or an index.
Abstract
We describe results from IMmotion150, a randomized phase 2 study of atezolizumab (anti-PD-L1) alone or combined with bevacizumab (anti-VEGF) versus sunitinib in 305 patients with treatment-naive metastatic renal cell carcinoma. Co-primary endpoints were progression-free survival (PFS) in intent-to-treat and PD-L1+ populations. Intent-to-treat PFS hazard ratios for atezolizumab + bevacizumab or atezolizumab monotherapy versus sunitinib were 1.0 (95% confidence interval (CI), 0.69-1.45) and 1.19 (95% CI, 0.82-1.71), respectively; PD-L1+ PFS hazard ratios were 0.64 (95% CI, 0.38-1.08) and 1.03 (95% CI, 0.63-1.67), respectively. Exploratory biomarker analyses indicated that tumor mutation and neoantigen burden were not associated with PFS. Angiogenesis, T-effector/IFN-γ response, and myeloid inflammatory gene expression signatures were strongly and differentially associated with PFS within and across the treatments. These molecular profiles suggest that prediction of outcomes with anti-VEGF and immunotherapy may be possible and offer mechanistic insights into how blocking VEGF may overcome resistance to immune checkpoint blockade.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several clinical trials have assessed the benefits of combining anti-angiogenic therapy with ICB and have demonstrated an increase in immune cell tumor infiltration and improved outcomes in patients with immune suppressed signatures compared to ICB alone”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as McDermott et al., 2018
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Robinson, M. D., McCarthy, D. J., & Smyth, G. K. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp616 · Cited by 41,364
limma powers differential expression analyses for RNA-sequencing and microarray studies
Ritchie, M. E., Phipson, B., Wu, D., Hu, Y., Law, C. W., Shi, W., & Smyth, G. K. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv007 · Cited by 40,458
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
The Ensembl Variant Effect Predictor
McLaren, W., Gil, L., Hunt, S. E., Riat, H. S., Ritchie, G. R. S., Thormann, A., Flicek, P., & Cunningham, F. (2016) · Genome Biology · doi:10.1186/s13059-016-0974-4 · Cited by 8,099
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
Self-citationPD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Cited by
VEGF in signaling and disease: beyond discovery and development
Apte, R. S., Chen, D. S., & Ferrara, N. (2019) · Cell · doi:10.1016/j.cell.2019.01.021 · Cited by 2,721
“Recent clinical studies have further supported the role of VEGF in anti-cancer immunity (McDermott et al., 2018).”
ResultSelf-citationThe evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Havel, J. J., Chowell, D., & Chan, T. A. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0116-x · Cited by 2,286
Top 10 Challenges in Cancer Immunotherapy
Hegde, P. S., & Chen, D. S. (2020) · Immunity · doi:10.1016/j.immuni.2019.12.011 · Cited by 2,238
Self-citationBagchi, S., Yuan, R., & Engleman, E. G. (2021) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-042020-042741 · Cited by 2,189
Hallmarks of response, resistance, and toxicity to immune checkpoint blockade
Morad, G., Helmink, B. A., Sharma, P., & Wargo, J. A. (2021) · Cell · doi:10.1016/j.cell.2021.09.020 · Cited by 1,648
Metadata
- Authors
- McDermott, D. F., Huseni, M. A., Atkins, M. B., Motzer, R. J., Rini, B. I., Escudier, B., Fong, L., Joseph, R. W., Pal, S. K., Reeves, J. A., Sznol, M., Hainsworth, J., Rathmell, W. K., Stadler, W. M., Hutson, T., Gore, M. E., Ravaud, A., Bracarda, S., Suárez, C., Danielli, R., Gruenwald, V., Choueiri, T. K., Nickles, D., Jhunjhunwala, S., Piault-Louis, E., Thobhani, A., Qiu, J., Chen, D. S., Hegde, P. S., Schiff, C., Fine, G. D., & Powles, T.
- Affiliations
- Beth Israel Deaconess Medical Center (US)
- Genentech (US)
- Georgetown Lombardi Comprehensive Cancer Center (US)
- Memorial Sloan Kettering Cancer Center (US)
- Cleveland Clinic (US)
- Institut Gustave Roussy (FR)
- University of California, San Francisco (US)
- Mayo Clinic in Florida (US)
- City Of Hope National Medical Center (US)
- Florida Cancer Specialists & Research Institute (US)
- Yale University (US)
- Sarah Cannon (US)
- Vanderbilt University Medical Center (US)
- University of Chicago (US)
- Royal Marsden Hospital (GB)
- Centre Hospitalier Universitaire de Bordeaux (FR)
- Universitat Autònoma de Barcelona (ES)
- Azienda Ospedaliera Universitaria Senese (IT)
- Medizinische Hochschule Hannover (DE)
- Dana-Farber Cancer Institute (US)
- Roche (United Kingdom) (GB)
- Queen Mary University of London (GB)
- Corresponding author
- McDermott, David F.
- ORCID
- McDermott, David F.
- Huseni, Mahrukh A.
- Atkins, Michael B.
- Motzer, Robert J.
- Rini, Brian I.
- Escudier, Bernard
- Fong, Lawrence
- Joseph, Richard W.
- Pal, Sumanta K.
- Reeves, James A.
- Sznol, Mario
- Hainsworth, John
- Rathmell, W. Kimryn
- Stadler, Walter M.
- Hutson, Thomas
- Ravaud, Alain
- Suárez, Cristina
- Danielli, Riccardo
- Choueiri, Toni K.
- Nickles, Dorothee
- Jhunjhunwala, Suchit
- Chen, Daniel S.
- Powles, Thomas
- Venue
- Nature Medicine
- Published
- 2018-06
- Volume
- 24
- Issue
- 6
- Pages
- 749-757
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC6721896
- OpenAlex
- W2805302875
- Cited by
- 1,260
- References
- 69
- Citations by year
- 2026: 83 · 2025: 100 · 2024: 127 · 2023: 168 · 2022: 227 · 2021: 195 · 2020: 203 · 2019: 117 · 2018: 37
- FWCI
- 103.97
- Type
- journal article
- Language
- en
- Update notices
- correction (2018-10-05)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institutes of Health
- National Cancer Institute (P50CA101942, P30CA008748, P30CA014599, P30CA068485)
- Topics
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
- Keywords
- atezolizumab, bevacizumab, sunitinib, metastatic renal cell carcinoma, PD-L1 blockade, anti-VEGF therapy, combination immunotherapy, progression-free survival, PD-L1 expression, tumor mutational burden, neoantigens, angiogenesis, IFN-gamma response, immune checkpoint inhibitor resistance, predictive biomarkers
- MeSH terms
- Bevacizumab, Sunitinib, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Renal Cell, Female, Humans, Kidney Neoplasms, Male, Middle Aged, Mutation, Gene Expression Regulation, Neoplastic, Treatment Outcome, Gene Expression Profiling, Kaplan-Meier Estimate, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. https://app.cochat.ai/papers/10.1038/s41591-018-0053-3
- The paper
- McDermott, D. F., Huseni, M. A., Atkins, M. B., Motzer, R. J., Rini, B. I., Escudier, B., Fong, L., Joseph, R. W., Pal, S. K., Reeves, J. A., Sznol, M., Hainsworth, J., Rathmell, W. K., Stadler, W. M., Hutson, T., Gore, M. E., Ravaud, A., Bracarda, S., Suárez, C., . . . Powles, T. (2018). Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nature Medicine. https://doi.org/10.1038/s41591-018-0053-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.